Delivery Order SPE2DB20D3103-SPE2DB25FQ1U1
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $1,288.86 to AmerisourceBergen Drug Corp for the supply of Envarsus XR 1 mg tablets (100-count packaging). This competitively awarded, firm fixed-price contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a comprehensive $999.99 billion pharmaceutical supply vehicle supporting military healthcare programs globally through December 2026....
- The Defense Logistics Agency awarded a delivery order valued at $1,165.05 to AmerisourceBergen Drug Corp for 30 tablets of Envarsus XR 1 mg on July 29, 2025, with an ultimate completion date of August 19, 2025. This firm fixed price delivery order carries no set-aside designation and represents a competitively awarded transaction under the company's larger indefinite delivery contract with DLA Troop Support Medical. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a...
- The Defense Logistics Agency awarded a delivery order valued at $1,718.48 to AmerisourceBergen Drug Corp for the supply of Envarsus XR 1 mg tablets (100-count units) on August 7, 2025, with completion expected by August 28, 2025. This firm fixed price delivery order represents a non-set-aside competitive award to the pharmaceutical distributor's Corporate Office division, with performance to be executed from the company's Conshohocken, Pennsylvania headquarters. The contract falls under...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on September 10, 2025, for the supply of Envarsus XR 1 mg tablets in quantities of 100 units, with a contract ceiling value of $1,718.48. This firm fixed-price delivery order, with an ultimate completion date of October 1, 2025, represents a non-set-aside competitive award to support federal medical procurement requirements. The award is issued under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order valued at $1,718.48 to AmerisourceBergen Drug Corp for 100 tablets of Envarsus XR 1 mg on August 4, 2025, with an ultimate completion date of August 25, 2025. The contract is structured as a firm fixed price delivery order with no set-aside designation, indicating it was competitively awarded. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform this work at its corporate office location. This delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 28, 2025, for the supply of Envarsus XR 1 mg tablets in quantities of 100 units. This competitively awarded, firm fixed-price delivery order carries a ceiling value of $1,718.48 and is scheduled for completion by September 19, 2025. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. As a child contract action under a larger vehicle, this...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 20, 2025, for the supply of Envarsus XR 1 mg tablets in a quantity of 100 units. This competitively awarded, non-set-aside contract carries a ceiling value of $1,718.48 with firm fixed pricing and is scheduled for completion by September 11, 2025. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract...
- The Defense Logistics Agency awarded a delivery order valued at $3,423.90 to AmerisourceBergen Drug Corp for the supply of Envarsus XR 4 mg tablets (100-count bottles) on August 25, 2025, with completion scheduled for September 16, 2025. This firm fixed-price delivery order represents a non-set-aside competitive award to the pharmaceutical distributor's corporate office in Conshohocken, Pennsylvania. The contract is issued as a child order under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 29, 2025, for the supply of Envarsus XR 1 mg tablets (100-count) with a ceiling value of $1,288.86. This non-set-aside, competitively awarded contract is structured as a firm fixed price delivery order with an ultimate completion date of September 22, 2025. The pharmaceutical product will be delivered to the company's corporate office location in Conshohocken, Pennsylvania. This delivery order is...
- The Defense Logistics Agency awarded a delivery order contract to AmerisourceBergen Drug Corp on June 2, 2025, for the supply of Envarsus XR 1 mg tablets (30-count packaging) with a ceiling value of $1,553.40. This is a firm fixed-price delivery order with an ultimate completion date of June 24, 2025, utilizing no set-aside designation. The contract represents a competitive award under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical, a $999.99 billion...
- SPE2DB20D3103Indefinite Delivery Contract
- SPE2DB20D3103-SPE2DB25FQ1U1Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $1.94K to AmerisourceBergen Drug Corp for the supply of Envarsus XR 1 mg tablets (30-count units) on September 5, 2025, with completion scheduled for September 26, 2025. This firm fixed-price delivery order represents a competitive award with no set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, fulfilled this order under its existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999.99M and extending through December 2026. This prime IDC serves as a comprehensive global pharmaceutical support vehicle enabling the company to supply pharmaceutical products and medical supplies to support military healthcare programs worldwide. The delivery order falls within AmerisourceBergen's extensive federal pharmaceutical procurement portfolio with DLA, which encompasses brand-name and generic medications, vaccines, and specialized medical supplies across multiple therapeutic domains. Envarsus XR is an immunosuppressant medication used to prevent organ rejection in transplant recipients, supporting the company's role as a critical vendor for federal medical procurement needs across the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. The award demonstrates the contractor's continued capability to meet federal requirements through open competition and deliver specialized pharmaceutical commodities to support military and veteran healthcare operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.9k | 9/5/25 |